A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia

NCT04117880 | Withdrawn Phase 2 FDA Drug

• 1 other identifier: PTC124-GD-028e- ANI
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a Phase 2, multicenter, open-label study evaluating the overall systemic and ocular safety profile of ataluren in nonsense mutation aniridia as determined by the incidences of treatment-emergent adverse events (TEAEs) as well as abnormal findings on laboratory assessments, vital signs, physical examinations, ophthalmoscopy, and slit-lamp examination. Participants who complete PTC124-GD-028 ANI (NCT02647359) meet all inclusion and none of the exclusion criteria will be enrolled into this study.

Conditions

Aniridia

Outcome Measures

Primary Outcomes (1)

• Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

  104 weeks

Secondary Outcomes (2)

• Change From Baseline in Visual Acuity at Week 104

  104 weeks

• Change From Baseline in Severity of Corneal Keratopathy at Week 104

  104 weeks

Study Arms (1)

Ataluren

EXPERIMENTAL

Ataluren Oral suspension taken 3 times per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20 mg/kg in the evening).

Drug: Ataluren

Interventions

Ataluren DRUG

Oral

Also known as: PTC124

Ataluren

Eligibility Criteria

• Age: 2 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants who will be selected for this study must meet the following criteria:
• Evidence of signed and dated informed consent document(s) indicating that the study candidate (and/or a parent/legal guardian) has been informed of all pertinent aspects of the study. Note: If the study candidate is considered a child under local regulation, a parent or legal guardian must provide written consent prior to initiation of study screening procedures and the study candidate may be required to provide written assent. The rules of the responsible institutional review board/independent ethics committee (IRB/IEC) regarding whether one or both parents must provide consent and the appropriate ages for obtaining consent and assent from the participant should be followed.
• Must have participated in and exited from Study PTC124-GD-028 ANI
• Age ≥2 years and of either gender.
• Body weight ≥12 kg.
• Willingness and ability to comply with scheduled visits, drug administration plan, study procedures, and study restrictions.
• Good general health.
• Female participants of childbearing potential are eligible for the study but must be willing to use adequate (at least 1 form of) contraceptive methods as described below during the study treatment period (starting from the day of first dose of study drug and ending 60 days after the last dose of study drug). Childbearing potential is defined as participants who have experienced menarche and who are neither postmenopausal or have been permanently sterilized.
• Hormonal methods of contraception (including oral and transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing intrauterine contraceptive devices \[IUDs\]) initiated at least 14 days prior to the first dose of study drug
• Abstinence
• Placement of a copper-containing IUD
• Condom with spermicidal foam/gel/film/cream/suppository
• Postmenopausal at least 12 months prior to first dose of study drug or permanently sterilized (for example, tubal occlusion, hysterectomy, bilateral salpingectomy)
• Male partner who has had a vasectomy for at least 3 months prior to the first dose of study drug
• Male participants with partners of childbearing potential must agree to use the following adequate (at least 1 form of) contraception during the study treatment period (starting from the day of first dose of study drug and ending 60 days after the last dose of study drug):

You may not qualify if:

• The presence of any of the following conditions will exclude a participant from study enrollment:
• Participation in any drug or device clinical investigation (other than Study PTC124-GD-028 ANI) within 90 days prior to Visit 1 (Screening) or anticipation of participating in any other drug or device clinical investigation during this study.
• Surgery within 30 days prior to enrollment.
• Female participants who are pregnant or breastfeeding. Female participants of childbearing potential must have a negative pregnancy test (beta-human chorionic gonadotropin \[β-HCG\]) at screening and must use adequate (at least 1 form of) contraceptive methods.
• Active ocular infection or inflammation.
• Prior or ongoing medical condition (for example, concomitant illness, alcoholism, drug abuse, psychiatric condition), medical history, physical findings, or laboratory abnormality that, in the Investigator's opinion, could adversely affect the safety of the participant, makes it unlikely that the course of study drug administration or follow-up would be completed, or could impair the assessment of study results.
• Participants with a positive result for hepatitis B, hepatitis C, or human immunodeficiency virus at Visit 1 (Screening).

Sponsors & Collaborators

• PTC Therapeutics: lead

MeSH Terms

Conditions

Aniridia

Interventions

ataluren

Condition Hierarchy (Ancestors)

Eye Abnormalities; Eye Diseases; Eye Diseases, Hereditary; Iris Diseases; Uveal Diseases; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Genetic Diseases, Inborn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 19, 2019
• First Posted: October 7, 2019
• Study Start: December 31, 2018
• Primary Completion: January 31, 2021
• Study Completion: January 31, 2021
• Last Updated: October 7, 2019

Record last verified: 2019-09